Caris Biorepository Research Protocol
The Caris Biorepository Research Protocol
1 other identifier
observational
100,000
1 country
38
Brief Summary
The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients. The Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2010
Longer than P75 for all trials
38 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2010
CompletedFirst Submitted
Initial submission to the registry
December 16, 2011
CompletedFirst Posted
Study publicly available on registry
December 26, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2035
January 21, 2026
January 1, 2026
20 years
December 16, 2011
January 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Develop biorepository that ensures molecular integrity and clinical relevance of quality human biospecimens and associated clinical data.
Retention of biospecimen samples with DNA
35 years
Implement release of specimens from biorepository for testing
Research for the purposes of cancer laboratory diagnostic tests.
35 years
Secondary Outcomes (6)
Laboratory testing
35 years
Laboratory testing
35 years
Laboratory testing
35 years
Laboratory testing
35 years
Laboratory testing
35 years
- +1 more secondary outcomes
Study Arms (5)
Normal
Donor samples reflective of a "normal" non-disease state
Newly Diagnosed Pan-Cancer Collection
Donor samples derived from treatment naïve patients with newly diagnosed solid tumors.
Early Detection Collection
Donor samples reflective of a population at increased risk for developing cancer.
Advanced Stage Cancer Collection
Donor samples derived from individuals with advanced stage cancer.
Minimal Residual Disease Collection
Donor samples obtained from individuals with a history of malignancy who are currently free of active disease
Eligibility Criteria
Healthy volunteers as well as those with a known disease state or condition
You may qualify if:
- years of age or older
- Capacity to provide informed consent
You may not qualify if:
- Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoners-patients will not be approached for participation in the Caris Biorepository.
- Minor subjects will not be included in the Caris Biorepository, as it is possible biospecimens and data may be stored beyond the time limitations of assent and it may be impracticable to re-consent these subjects once they become adults.
- Individuals who lack the capacity to give informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (38)
University of South Alabama
Mobile, Alabama, United States
Southwest Medical Imaging
Scottsdale, Arizona, United States
St. Bernards Medical Center
Jonesboro, Arkansas, United States
CARTI Cancer Center
Little Rock, Arkansas, United States
ObjectiveHealth - ARcare Center for Clinical Research
Little Rock, Arkansas, United States
Lee Memorial Health System
Fort Myers, Florida, United States
Cancer Care of North Florida
Lake City, Florida, United States
Advent Health
Orlando, Florida, United States
The University of South Florida
Tampa, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701, United States
Emory University
Atlanta, Georgia, United States
Augusta University Research Institute
Augusta, Georgia, United States
Cancer Center of Middle Georgia
Dublin, Georgia, United States
Hope and Healing Cancer Services
Hinsdale, Illinois, United States
CHRISTUS - St. Frances Cabrini Hospital
Alexandria, Louisiana, United States
Tulane University
New Orleans, Louisiana, United States
CHRISTUS - Highland Medical Center
Shreveport, Louisiana, United States
Mercy Medical Center
Baltimore, Maryland, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
Hattiesburg Clinic
Hattiesburg, Mississippi, United States
Jackson Oncology Associates
Jackson, Mississippi, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
ObjectiveHealth - Premier Health Research
Sparta, New Jersey, United States
CHRISTUS - St. Vincent Regional Cancer Center
Santa Fe, New Mexico, United States
St. Lawrence Health System
Potsdam, New York, United States
National Translational Research Group
Ridge, New York, United States
Altru Health System
Grand Forks, North Dakota, United States
NEO Urology Associates
Boardman, Ohio, United States
Great Lakes Medical Research
Cleveland, Ohio, United States
Bend Memorial Clinic
Bend, Oregon, United States
Clinical Biotechnology Research Institute at RSFH
Charleston, South Carolina, United States
Spartanburg Regional Health Services
Spartanburg, South Carolina, United States
West Cancer Center
Germantown, Tennessee, United States
ObjectiveHealth - Amarillo Premier Research
Amarillo, Texas, United States
CHRISTUS - St. Michael's Health
Texarkana, Texas, United States
CAMC Clinical Trials
Charleston, West Virginia, 25304, United States
Mercy Health
Janesville, Wisconsin, United States
Biospecimen
Currently plasma with an opportunity to collect other biospecimens
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Matthew Oberley, MD
Caris Life Sciences
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 16, 2011
First Posted
December 26, 2011
Study Start
November 1, 2010
Primary Completion (Estimated)
November 1, 2030
Study Completion (Estimated)
November 1, 2035
Last Updated
January 21, 2026
Record last verified: 2026-01